AU763435B2 - Methods for preventing/treating damage to sensory hair cells and cochlear neurons - Google Patents

Methods for preventing/treating damage to sensory hair cells and cochlear neurons Download PDF

Info

Publication number
AU763435B2
AU763435B2 AU60532/99A AU6053299A AU763435B2 AU 763435 B2 AU763435 B2 AU 763435B2 AU 60532/99 A AU60532/99 A AU 60532/99A AU 6053299 A AU6053299 A AU 6053299A AU 763435 B2 AU763435 B2 AU 763435B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
independently selected
ring
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU60532/99A
Other languages
English (en)
Other versions
AU6053299A (en
Inventor
Robert L Hudkins
Ulla Pirvola
Mart Saarma
Kevin Walton
Jukka Ylikoski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22286288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU763435(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of AU6053299A publication Critical patent/AU6053299A/en
Application granted granted Critical
Publication of AU763435B2 publication Critical patent/AU763435B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
AU60532/99A 1998-09-25 1999-09-24 Methods for preventing/treating damage to sensory hair cells and cochlear neurons Ceased AU763435B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10176398P 1998-09-25 1998-09-25
US60/101763 1998-09-25
PCT/US1999/021780 WO2000018407A1 (en) 1998-09-25 1999-09-24 Methods for preventing/treating damage to sensory hair cells and cochlear neurons

Publications (2)

Publication Number Publication Date
AU6053299A AU6053299A (en) 2000-04-17
AU763435B2 true AU763435B2 (en) 2003-07-24

Family

ID=22286288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60532/99A Ceased AU763435B2 (en) 1998-09-25 1999-09-24 Methods for preventing/treating damage to sensory hair cells and cochlear neurons

Country Status (13)

Country Link
US (2) US6448283B1 (https=)
EP (1) EP1126855B1 (https=)
JP (2) JP2002525329A (https=)
KR (1) KR100628847B1 (https=)
CN (1) CN1329034C (https=)
AT (1) ATE361752T1 (https=)
AU (1) AU763435B2 (https=)
CA (1) CA2345295C (https=)
DE (1) DE69936059T2 (https=)
ES (1) ES2288042T3 (https=)
HK (1) HK1040053B (https=)
NZ (1) NZ511024A (https=)
WO (1) WO2000018407A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
US7129225B2 (en) * 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US20100030301A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Electrical stimulation for modulation of neural plasticity
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US20100030130A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Pharmaceutical intervention for modulation of neural plasticity
US20050171579A1 (en) * 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
DE60332215D1 (de) 2002-02-28 2010-06-02 Eisai R&D Man Co Ltd Neue indazolverbindungen mit kondensiertem ring
EP1585431A2 (en) * 2002-10-10 2005-10-19 Neurorecovery, Inc. System and method of active neuro-protection for detecting and arresting traumatic brain injury and spinal cord injury
CA2569724A1 (en) 2004-06-15 2005-12-29 Cochlear Americas Automatic determination of the threshold of an evoked neural response
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
DE102010007281A1 (de) * 2010-02-08 2011-08-11 EMC microcollections GmbH, 72070 Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
ES2870085T3 (es) 2013-06-26 2021-10-26 Xigen Inflammation Ltd Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN110248650A (zh) 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
WO1993008809A1 (en) 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
DE69409641T2 (de) 1993-05-28 1998-11-26 Cephalon, Inc., West Chester, Pa. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
AU1911095A (en) 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5686444A (en) * 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
US5929041A (en) 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
PT912184E (pt) 1996-06-25 2002-12-31 Cephalon Inc Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
AU758241B2 (en) 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles

Also Published As

Publication number Publication date
JP2011126893A (ja) 2011-06-30
US20020115706A1 (en) 2002-08-22
CN1329034C (zh) 2007-08-01
ES2288042T3 (es) 2007-12-16
EP1126855A1 (en) 2001-08-29
US7789610B2 (en) 2010-09-07
KR100628847B1 (ko) 2006-09-29
AU6053299A (en) 2000-04-17
KR20010085848A (ko) 2001-09-07
HK1040053B (en) 2007-09-21
WO2000018407A1 (en) 2000-04-06
EP1126855A4 (en) 2004-05-19
EP1126855B1 (en) 2007-05-09
NZ511024A (en) 2003-10-31
CA2345295A1 (en) 2000-04-06
DE69936059T2 (de) 2008-01-24
JP2002525329A (ja) 2002-08-13
CN1328461A (zh) 2001-12-26
JP5190125B2 (ja) 2013-04-24
DE69936059D1 (de) 2007-06-21
ATE361752T1 (de) 2007-06-15
US6448283B1 (en) 2002-09-10
HK1040053A1 (en) 2002-05-24
WO2000018407A9 (en) 2000-09-21
CA2345295C (en) 2009-12-15

Similar Documents

Publication Publication Date Title
AU763435B2 (en) Methods for preventing/treating damage to sensory hair cells and cochlear neurons
RU2757276C2 (ru) Способы лечения кохлеарной синаптопатии
JP7474289B2 (ja) カリウムチャンネル開口薬としての有用な新規化合物
CN118696029A (zh) 化合物
AU2009277086A1 (en) Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
KR20150004441A (ko) Ｐｄｅ４의 바이사이클릭 헤테로아릴 억제제
JP7600282B2 (ja) ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
BR112021006092A2 (pt) composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados
US12502433B2 (en) Phosphonate-drug conjugates
JP2010520154A (ja) 神経変性疾患のためのａｍｐａレセプターアンタゴニストおよびｎｍｄａレセプターアンタゴニスト
WO2015029948A1 (ja) 網膜色素上皮の障害を原因とする網膜疾患の予防または治療剤
US10434097B1 (en) Methods and compositions for treating hearing disorders
WO2021127275A1 (en) Gsk-3 modulator otic formulations
JP7158723B2 (ja) 耳疾患の処置における使用のための（＋）－アザセトロン
RU2779111C2 (ru) Новые соединения, используемые в качестве открывателей калиевых каналов
RU2779131C2 (ru) Новые соединения, используемые в качестве открывателей калиевых каналов
WO2025233641A1 (en) Novel photoinducible kinase inhibitors for treating proliferative and vasoproliferative diseases
US20130005698A1 (en) Pharmaceutical for preventing or treating an inner ear disorder

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)